# Exploring the Role of Retatrutide in Targeting the LPI/GPR55 Axis in Liver Disease

Canonical source: https://retacompare.com/research/exploring-the-role-of-retatrutide-in-targeting-the-lpi-gpr55-axis-in-liver-disease

Mechanism & Pharmacology · 2026-04-01


    Retatrutide may offer therapeutic potential by targeting the LPI/GPR55 axis in metabolic dysfunction-associated fatty liver disease (MAFLD). This axis plays a critical role in the progression of liver diseases such as metabolic-associated steatohepatitis (MASH), which has implications for treatment strategies involving novel agents like retatrutide.

 What this source covers

The source discusses the emerging understanding of metabolic dysfunction-associated fatty liver disease (MAFLD), which has been redefined from non-alcoholic fatty liver disease (NAFLD). It highlights the significance of the L-α-lysophosphatidylinositol/G protein-coupled receptor 55 (LPI/GPR55) axis in the pathophysiology of liver diseases, particularly in the context of hepatic lipid accumulation, inflammation, and fibrosis. The review also addresses the modulation of this axis by the enzyme membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) and the recent advancements in pharmacologic treatments for MASH.

 Why it matters for Retatrutide research

The research on the LPI/GPR55 axis provides critical insights into potential therapeutic strategies for MAFLD and MASH, where retatrutide may play a role. Given its involvement in hepatic processes such as de novo lipogenesis and inflammation, targeting this axis could enhance the efficacy of retatrutide in managing liver disease. The source emphasizes that while there have been advancements in pharmacologic treatments, including FDA-approved agents like resmetirom and semaglutide, the exploration of retatrutide in this context remains promising.

 Key findings or claims

The LPI/GPR55 axis is implicated in liver disease progression, influencing lipid accumulation and inflammation.

MBOAT7 exacerbates hepatic steatosis and insulin resistance by modulating the LPI/GPR55 axis.

Recent FDA approvals for MASH treatments highlight a growing interest in pharmacologic interventions.

Targeting the endocannabinoidome, specifically the LPI/GPR55 axis, presents a novel therapeutic strategy.

Previous therapeutic attempts to target GPR55 have faced challenges due to its context-specific roles across tissues.

 Context and prior work

The exploration of the LPI/GPR55 axis aligns with broader research on glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) pathways, which are relevant in the context of metabolic health and liver disease. Retatrutide, as a dual agonist, may interact with these pathways, enhancing its therapeutic potential for conditions like MAFLD. Previous studies have indicated that GLP-1 receptor agonists can improve liver histology, suggesting a potential synergy with retatrutide's mechanisms.

 Practical takeaways for researchers

For researchers investigating retatrutide, understanding the mechanistic role of the LPI/GPR55 axis is essential. Future studies should focus on hepatic-specific modulation of this axis to optimize therapeutic outcomes. Additionally, the development of selective ligands and advanced delivery systems may mitigate off-target effects, enhancing the efficacy of retatrutide in liver disease management.

 FAQ

 What is the LPI/GPR55 axis?

The LPI/GPR55 axis refers to the interaction between L-α-lysophosphatidylinositol and the G protein-coupled receptor 55, which plays a significant role in liver disease progression.

 How does retatrutide relate to liver disease?

Retatrutide may target pathways involved in metabolic dysfunction associated with liver diseases, potentially improving treatment outcomes for conditions like MAFLD and MASH.

 What are the implications of MBOAT7 in liver disease?

MBOAT7 modulates the LPI/GPR55 axis, exacerbating conditions such as hepatic steatosis and insulin resistance, which are critical factors in liver disease progression.

 Source: PubMed · Liver Int · published 2026-04-01.

## Sources

- PubMed · Liver Int: https://pubmed.ncbi.nlm.nih.gov/41823054